ADVANCED OR METASTATIC NSCLC
Clinical trials for ADVANCED OR METASTATIC NSCLC explained in plain language.
Never miss a new study
Get alerted when new ADVANCED OR METASTATIC NSCLC trials appear
Sign up with your email to follow new studies for ADVANCED OR METASTATIC NSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo shows promise for Tough-to-Treat lung cancer
Disease control OngoingThis phase 2 trial tests a combination of two drugs—ceralasertib (a pill) and durvalumab (an infusion)—in 39 adults with advanced or metastatic non-small cell lung cancer that has worsened after standard treatments like immunotherapy and chemotherapy. The main goal is to see if t…
Matched conditions: ADVANCED OR METASTATIC NSCLC
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail shows promise for tough lung cancer
Disease control OngoingThis early-stage trial is testing a combination of two drugs—datopotamab deruxtecan (Dato-DXd) and pembrolizumab (Keytruda)—with or without standard chemotherapy in people with advanced non-small cell lung cancer. The goal is to see if the combination is safe and can shrink tumor…
Matched conditions: ADVANCED OR METASTATIC NSCLC
Phase: PHASE1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug cocktail shows early promise for tough lung cancer
Disease control OngoingThis early-stage trial is testing a new drug called datopotamab deruxtecan (Dato-DXd) combined with immunotherapy, with or without chemotherapy, in 155 people with advanced non-small cell lung cancer. The goal is to see if the combination is safe and shows signs of shrinking tumo…
Matched conditions: ADVANCED OR METASTATIC NSCLC
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC